content: SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
                       -------------------------------------------
  
  
                                      FORM 8-K
  
  
                                   CURRENT REPORT
  
                         Pursuant to Section 13 or 15(d) of
                         the Securities Exchange Act of 1934
  
  
  
                                   Date of Report
                         (Date of earliest event reported):
  
                                    May 1, 2000
                      ----------------------------------------
  
  
                                   THERMEDICS INC.
                   (Exact name of Registrant as specified in its charter)
  
  
  
  Massachusetts                      1-9567                             04-2788806
  (State or other            (Commission File Number)             (I.R.S. Employer
  jurisdiction of                                            Identification Number
  incorporation or)
  organization)
  
  
  470 Wildwood Street,
  P.O. Box 2999
  Woburn, Massachusetts                                                      01888
  (Address of principal                                                 (Zip Code)
  executive offices)
  
                                   (781) 622-1000
                           (Registrant's telephone number
                                including area code)
  
  
  
  <PAGE>
  
  
  
  
  
  This Form 8-K contains forward-looking statements that involve a number of risks
  and  uncertainties.  Important factors that could cause actual results to differ
  materially from those indicated by such forward-looking statements are set forth
  under the  heading  "Forward-looking  Statements"  in Exhibit  13 to  Thermedics
  Inc.'s  Annual  Report on Form 10-K for the year ended  January  1, 2000.  These
  include risks and uncertainties  relating to: government regulation and industry
  standards,  competition and technological change,  intellectual property rights,
  reimbursement by insurers for medical procedures,  medical community  acceptance
  of medical devices, availability of materials and components, product liability,
  international operations,  the company's acquisition strategy, and the company's
  cash management arrangement with Thermo Electron.
  
  Item 5.     Other Events
  
       On April 7, 2000, the Registrant issued a press release, attached hereto as
  Exhibit 99, regarding its financial results for the guarter ended April 1, 2000.
  
  Item 7.     Financial Statements, Pro Forma Financial Information and Exhibits
  
        (a)   Financial Statements of Business Acquired: not applicable.
  
        (b)   Pro Forma Financial Information: not applicable.
  
        (c)   Exhibits
  
              99 Press Release dated April 1, 2000.
  
  
  <PAGE>
  
  
  
                                      SIGNATURE
  
  
        Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned, thereunto duly authorized, on this 2nd day of May, 2000.
  
                                               THERMEDICS INC
  
                                               By:  /s/ Theo Melas-Kyriazi
                                                    ------------------------------
                                                    Theo Melas-Kyriazi
                                                    Chief Financial Officer
  
  
  
  
  <PAGE>
  
  
                                                                        Exhibit 99
  
  
  Investor Contact: 781-6 22-1111
  Media Contact: 781-622-1252
  
  
                     Thermedics Announces First Quarter Results
  
  WOBURN,  Mass.,  May 1, 2000 -  Thermedics  Inc.  (ASE-TMD),  a Thermo  Electron
  company,  today reported that revenues for the quarter ended April 1, 2000, were
  $60.7  million,  compared  with $52.0  million in 1999.  Income from  continuing
  operations,  which excludes the results of the company's  power  electronics and
  test equipment and  heart-assist  and blood testing devices  segments because of
  plans to sell these  businesses,  was $2.7 million,  or $.06 per diluted  share,
  compared  with $1.7 million,  or $.04 per diluted  share,  last year.  Excluding
  pretax  restructuring and unusual costs of $0.1 million in 2000 and $1.4 million
  in 1999, income from continuing operations would have been $2.7 million, or $.06
  per diluted share, in 2000 and $3.1 million, or $.07 per diluted share, in 1999.
  
  
  Consolidated Statement of Income (unaudited)
  
                                                          Three Months Ended
  
  (In thousands except per share amounts)          April 1, 2000   April 3, 1999
  
  Revenues                                            $ 60,729        $ 51,960
                                                      --------        --------
  
  Costs and Operating Expenses:
    Cost of revenues                                    32,245          28,018
    Selling, general, and administrative expenses       18,409          15,162
    Research and development expenses                    4,466           3,404
    Restructuring and unusual costs                         93           1,395
                                                      --------        --------
                                                        55,213          47,979
                                                      --------        --------
  
  Operating Income                                       5,516           3,981
  Interest Income                                        1,046           1,051
  Interest Expense                                        (891)           (427)
  Equity in Earnings (Loss) of Unconsolidated
   Subsidiaries                                             65             (21)
                                                      --------        --------
  
  Income from Continuing Operations Before
   Provision for Income Taxes and Minority Interest      5,736           4,584
  Provision for Income Taxes                             2,479           2,304
  Minority Interest Expense                                566             588
                                                      --------        --------
  
  Income from Continuing Operations                      2,691           1,692
  Income from Discontinued Operations (net of
   income tax provision and minority interest
   of $1,581)                                              -               890
                                                      --------        --------
  Net Income                                          $  2,691        $  2,582
                                                      ========        ========
  
  Earnings per Share from Continuing Operations:
    Basic                                             $    .06        $    .04
                                                      ========        ========
    Diluted                                           $    .06        $    .04
                                                      ========        ========
  Earnings per Share:
    Basic                                             $    .06        $    .06
                                                      ========        ========
    Diluted                                           $    .06        $    .06
                                                      ========        ========
  Weighted Average Shares:
    Basic                                               41,982          41,696
                                                      ========        ========
    Diluted                                             42,981          42,806
                                                      ========        ========
  
       Note: The company's power  electronics and test equipment and  heart-assist
  and blood  testing  devices  segments  have  been  classified  as  "discontinued
  operations"  because of the company's plans to sell these  businesses.  The 1999
  results have been restated to reflect this accounting treatment.
  <PAGE>
  
        Thermedics Inc. develops, manufactures, and markets diverse product lines,
  including  implantable  heart-assist  devices  and  other  biomedical  products,
  security  instruments,  and equipment that assures the quality of a wide variety
  of consumer  products and bulk materials.  Thermedics is a public  subsidiary of
  Thermo Electron  Corporation.  More  information is available on the Internet at
  http://www.thermo.com/subsid/tmd1.html.
  
  The following constitutes a "Safe Harbor" statement under the Private Securities
  Litigation  Reform Act of 1995:  This  press  release  contains  forward-looking
  statements that involve a number of risks and  uncertainties.  Important factors
  that could cause actual  results to differ  materially  from those  indicated by
  such forward-looking statements are set forth under the heading "Forward-looking
  Statements"  in Exhibit 13 to the  company's  annual report on Form 10-K for the
  year ended January 1, 2000. These include risks and  uncertainties  relating to:
  government  regulation and industry  standards,  competition  and  technological
  change,  intellectual  property  rights,  reimbursement  by insurers for medical
  procedures,  medical  community  acceptance of medical devices,  availability of
  materials and  components,  product  liability,  international  operations,  the
  company's  acquisition strategy,  and the company's cash management  arrangement
  with Thermo Electron.
metadata_documents: [{"type": "8-K", "sequence": "1", "description": "FORM 8-K", "secsgml_size_bytes": 9350}]
metadata_filer: {"company-data": {"conformed-name": "THERMEDICS INC", "cik": "0000721356", "assigned-sic": "3590", "irs-number": "042788806", "state-of-incorporation": "MA", "fiscal-year-end": "0102"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-09567", "film-number": "616439"}, "business-address": {"street1": "470 WILDWOOD ST", "street2": "P O BOX 2697", "city": "WOBURN", "state": "MA", "zip": "01888-1799", "phone": "7816221000"}, "mail-address": {"street1": "81 WYMAN STREET", "street2": "P.O. BOX 9046", "city": "WALTHAM", "state": "MA", "zip": "02254"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
                       -------------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                         Pursuant to Section 13 or 15(d) of
                         the Securities Exchange Act of 1934
  
                                   Date of Report
                         (Date of earliest event reported):
  
                                    May 1, 2000
                      ----------------------------------------
  
                                   THERMEDICS INC.
                   (Exact name of Registrant as specified in its charter)
  
  Massachusetts                      1-9567                             04-2788806
  (State or other            (Commission File Number)             (I.R.S. Employer
  jurisdiction of                                            Identification Number
  incorporation or)
  organization)
  
  470 Wildwood Street,
  P.O. Box 2999
  Woburn, Massachusetts                                                      01888
  (Address of principal                                                 (Zip Code)
  executive offices)
  
                                   (781) 622-1000
                           (Registrant's telephone number
                                including area code)
  This Form 8-K contains forward-looking statements that involve a number of risks
  and  uncertainties.  Important factors that could cause actual results to differ
  materially from those indicated by such forward-looking statements are set forth
  under the  heading  "Forward-looking  Statements"  in Exhibit  13 to  Thermedics
  Inc.'s  Annual  Report on Form 10-K for the year ended  January  1, 2000.  These
  include risks and uncertainties  relating to: government regulation and industry
  standards,  competition and technological change,  intellectual property rights,
  reimbursement by insurers for medical procedures,  medical community  acceptance
  of medical devices, availability of materials and components, product liability,
  international operations,  the company's acquisition strategy, and the company's
  cash management arrangement with Thermo Electron.
  
  Item 5.     Other Events
  
       On April 7, 2000, the Registrant issued a press release, attached hereto as
  Exhibit 99, regarding its financial results for the guarter ended April 1, 2000.
  
  Item 7.     Financial Statements, Pro Forma Financial Information and Exhibits
  
        (a)   Financial Statements of Business Acquired: not applicable.
  
        (b)   Pro Forma Financial Information: not applicable.
  
        (c)   Exhibits
  
              99 Press Release dated April 1, 2000.
  SIGNATURE
  
        Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned, thereunto duly authorized, on this 2nd day of May, 2000.
  
                                               THERMEDICS INC
  
                                               By:  /s/ Theo Melas-Kyriazi
                                                    ------------------------------
                                                    Theo Melas-Kyriazi
                                                    Chief Financial Officer
  Exhibit 99
  
  Investor Contact: 781-6 22-1111
  Media Contact: 781-622-1252
  
                     Thermedics Announces First Quarter Results
  
  WOBURN,  Mass.,  May 1, 2000 -  Thermedics  Inc.  (ASE-TMD),  a Thermo  Electron
  company,  today reported that revenues for the quarter ended April 1, 2000, were
  $60.7  million,  compared  with $52.0  million in 1999.  Income from  continuing
  operations,  which excludes the results of the company's  power  electronics and
  test equipment and  heart-assist  and blood testing devices  segments because of
  plans to sell these  businesses,  was $2.7 million,  or $.06 per diluted  share,
  compared  with $1.7 million,  or $.04 per diluted  share,  last year.  Excluding
  pretax  restructuring and unusual costs of $0.1 million in 2000 and $1.4 million
  in 1999, income from continuing operations would have been $2.7 million, or $.06
  per diluted share, in 2000 and $3.1 million, or $.07 per diluted share, in 1999.
  
  Consolidated Statement of Income (unaudited)
  
                                                          Three Months Ended
  
  (In thousands except per share amounts)          April 1, 2000   April 3, 1999
  
  Revenues                                            $ 60,729        $ 51,960
                                                      --------        --------
  
  Costs and Operating Expenses:
    Cost of revenues                                    32,245          28,018
    Selling, general, and administrative expenses       18,409          15,162
    Research and development expenses                    4,466           3,404
    Restructuring and unusual costs                         93           1,395
                                                      --------        --------
                                                        55,213          47,979
                                                      --------        --------
  
  Operating Income                                       5,516           3,981
  Interest Income                                        1,046           1,051
  Interest Expense                                        (891)           (427)
  Equity in Earnings (Loss) of Unconsolidated
   Subsidiaries                                             65             (21)
                                                      --------        --------
  
  Income from Continuing Operations Before
   Provision for Income Taxes and Minority Interest      5,736           4,584
  Provision for Income Taxes                             2,479           2,304
  Minority Interest Expense                                566             588
                                                      --------        --------
  
  Income from Continuing Operations                      2,691           1,692
  Income from Discontinued Operations (net of
   income tax provision and minority interest
   of $1,581)                                              -               890
                                                      --------        --------
  Net Income                                          $  2,691        $  2,582
                                                      ========        ========
  
  Earnings per Share from Continuing Operations:
    Basic                                             $    .06        $    .04
                                                      ========        ========
    Diluted                                           $    .06        $    .04
                                                      ========        ========
  Earnings per Share:
    Basic                                             $    .06        $    .06
                                                      ========        ========
    Diluted                                           $    .06        $    .06
                                                      ========        ========
  Weighted Average Shares:
    Basic                                               41,982          41,696
                                                      ========        ========
    Diluted                                             42,981          42,806
                                                      ========        ========
  
       Note: The company's power  electronics and test equipment and  heart-assist
  and blood  testing  devices  segments  have  been  classified  as  "discontinued
  operations"  because of the company's plans to sell these  businesses.  The 1999
  results have been restated to reflect this accounting treatment.
  Thermedics Inc. develops, manufactures, and markets diverse product lines,
  including  implantable  heart-assist  devices  and  other  biomedical  products,
  security  instruments,  and equipment that assures the quality of a wide variety
  of consumer  products and bulk materials.  Thermedics is a public  subsidiary of
  Thermo Electron  Corporation.  More  information is available on the Internet at
  http://www.thermo.com/subsid/tmd1.html.
  
  The following constitutes a "Safe Harbor" statement under the Private Securities
  Litigation  Reform Act of 1995:  This  press  release  contains  forward-looking
  statements that involve a number of risks and  uncertainties.  Important factors
  that could cause actual  results to differ  materially  from those  indicated by
  such forward-looking statements are set forth under the heading "Forward-looking
  Statements"  in Exhibit 13 to the  company's  annual report on Form 10-K for the
  year ended January 1, 2000. These include risks and  uncertainties  relating to:
  government  regulation and industry  standards,  competition  and  technological
  change,  intellectual  property  rights,  reimbursement  by insurers for medical
  procedures,  medical  community  acceptance of medical devices,  availability of
  materials and  components,  product  liability,  international  operations,  the
  company's  acquisition strategy,  and the company's cash management  arrangement
  with Thermo Electron.